Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an update.
Pharmaron Beijing Co., Ltd. has updated details of its proposed final cash dividend for the financial year ended 31 December 2025, setting the payout at RMB 2 per 10 shares, subject to shareholder approval at the annual general meeting on 12 June 2026. The company has fixed the ex-dividend date for 7 July 2026, with a record date of 15 July 2026 and an expected payment date of 7 August 2026, while outlining specific withholding tax rates for different categories of mainland and overseas investors accessing its H shares and A shares via Stock Connect, clarifying the net returns shareholders can expect.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based pharmaceutical services company listed in Hong Kong, operating in the life sciences and biotech sector. It focuses on providing research, development and manufacturing services to global drug developers, with its H shares traded on the Hong Kong Stock Exchange and subject to cross-border investment and tax arrangements.
Average Trading Volume: 6,007,989
Technical Sentiment Signal: Sell
Current Market Cap: HK$51.05B
See more data about 3759 stock on TipRanks’ Stock Analysis page.